Navigation Links
Rules-Based Medicine Launches OncologyMAP® to Advance Cancer-Related Drug and Diagnostic Development
Date:3/24/2011

AUSTIN, Texas, March 24, 2011 /PRNewswire/ -- Rules-Based Medicine, Inc. (RBM), a leading provider of innovative biomarker solutions, today formally announced the global launch of OncologyMAP®, a powerful tool developed at the direction of and with funding from the National Cancer Institute. Through quantitative measurement of 101 cancer-related proteins, OncologyMAP® provides researchers with unprecedented data on biological pathways that could hold the key to understanding the molecular basis of cancer.  OncologyMAP® was released to a limited number of key customers in October, and RBM has received positive feedback from clients who report valuable results in their studies for drug re-tasking, indication expansion, and patient stratification using this cost-effective, comprehensive testing service. 

"The use of biomarker tools throughout drug development is a requirement for researchers who must balance leaner R&D budgets with the greater demands for safety, innovation and success," said Craig Benson, RBM president and chief executive officer. "From one drop of serum, OncologyMAP® can deliver data that could help solve therapeutic and diagnostic dilemmas related to cancer making this biomarker panel an essential component of the development toolkit."

OncologyMAP® provides drug researchers with an accurate and affordable means of evaluating the efficacy and safety of therapeutic candidates. The test is validated to clinical laboratory standards enabling biomarker pattern discoveries made in basic research to be reproducibly extended into clinical trials. The use of sensitive, reproducible biomarker patterns as objective measures of drug efficacy and toxicity can accelerate development efforts and facilitate decision-making to avoid costs associated with late-stage drug attrition.

OncologyMAP® is based on RBM's proprietary Multi-Analyte Profiling (MAP) platform, which quantifies key blood-based biomarkers representing dozens of important biological pathways. The multiplexing process allows for heightened efficiency while providing excellent accuracy and precision.

This project was supported with Federal Funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contracts No. HHSN261200700037C and HHSN261200800045C.

About Rules-Based Medicine, Inc.

Rules-Based Medicine's biomarker testing service provides clinical researchers, physicians and healthcare providers with reproducible, quantitative, multiplexed data for hundreds of proteins to advance drug development and patient care. The Company's proprietary Multi Analyte Profiling (MAP) technology offers pre-clinical and clinical researchers broad, cost-effective protein analyses in multiple species from a small sample volume. MAP technology also supports RBM's drive to develop diagnostics that aid in the detection of complex diseases and conditions in areas of unmet medical need such as neuropsychiatry, nephrology, immunology and cardiology. RBM's initial molecular diagnostic test, VeriPsych™, is a blood-based test that aids in the confirmation of diagnosis of recent-onset schizophrenia by evaluating a proprietary set of 51 biomarkers. RBM also offers innovative and proprietary ex vivo testing systems such as TruCulture™, the first fully-closed, reproducible whole blood culture system. More information about RBM is located at www.rulesbasedmedicine.com.


'/>"/>
SOURCE Rules-Based Medicine, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Rules-Based Medicine, Inc. Launches Human Kidney Damage Biomarker Panel
2. Rules-Based Medicine, Inc. Launches DiscoveryMAP(TM) Service for Drug and Diagnostic Development
3. The Science of Music Meets the Art of Medicine - ARIMM 3rd Annual Conference at IPFW, September 12-13, 2008
4. China Medicine Announces Strong Second Quarter 2008 Results
5. Regenerative Medicine Appoints Cell Therapy Group Consultant to Editorial Board
6. As personalized, genomic medicine takes off, four developing countries show the way for others
7. Connecticut State Medical Society and Genomas Co-Sponsor Forum on DNA-Guided Medicine and the Path to Personalized Health Care
8. New Report on 633 Biotechnology Medicines Under Development Released in Michigan
9. [video] Ronald Andrews, CEO of Clarient, Inc. Discusses Agreement With University of Pennsylvania School of Medicine on WallSt.nets 3-Minute Press Show
10. China Medicine to Showcase Bethin Weight Loss Product at 2008 Natural Products Expo East Trade Show
11. Dr. Larry Corey Named New Member of the Institutes of Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2016)... 30, 2016 The global Pyrogen ... hold a dominant share in the overall market. The ... Inc., and Merck KGaA, held a lion,s share of ... Research observes that these companies are expected to retain ... that are do not require rabbit pyrogen testing along ...
(Date:11/30/2016)... Equicare Health Inc ., the leading supplier of comprehensive ... the top 100 companies in the 2016 Global Digital ... top digital health companies across the globe.   ... continually upgrading our product with the ongoing digital shift ... Len Grenier , CEO of Equicare Health, "It,s ...
(Date:11/30/2016)... Part of 5m$ Investment in Integrated Drug Discovery ... , ... announced that it had successfully completed the expansion of their ... the Screening Collection to over 400,000. The new compounds were ... company. This expansion, complemented by new robotics and compound management ...
(Date:11/30/2016)... , ... November 30, 2016 , ... ... the development of a new orally administered treatment for Alzheimer’s disease (AD), today ... of a Phase 2a clinical trial of T3D-959 in mild to moderate Alzheimer’s ...
Breaking Biology Technology:
(Date:11/19/2016)... Securus Technologies, a leading provider of civil and criminal ... monitoring, announced today that it has offered a challenge ... technology judge determine who has the largest and best ... platform, and the best customer service. "ICSolutions ... we do – which clearly is not the case ...
(Date:11/15/2016)... 2016 Research and Markets has announced the ... report to their offering. ... The ... 2021 from USD 6.21 Billion in 2016, growing at a CAGR ... the bioinformatics market is driven by the growing demand for nucleic ...
(Date:6/22/2016)... 2016   Acuant , the leading ... has partnered with RightCrowd ® to ... Management, Self-Service Kiosks and Continuous Workforce Assurance. ... functional enhancements to existing physical access control ... with an automated ID verification and authentication ...
Breaking Biology News(10 mins):